Nick Porter, president of World Courier, and Chris Williams, SVP and international MD of Alloga Europe and ICS (all a part of AmerisourceBergen), discuss the heightened demand for cold chain and cryogenic storage to support advanced therapy medicinal products (ATMPs), and the essential investments in technology solutions needed to safeguard the supply chain.
Key insights:
- Recent reports suggest cold chain products will continue to grow at twice the rate of non-cold chain products through 2024, creating a heightened demand for cold chain logistics.
- Successful cold chain logistics requires highly choreographed shipping schedules, cold storage infrastructure, temperature-controlled packaging, tracking technology and adherence to strict regulatory guidelines.
- Biopharma companies and logistics providers can deploy a wide range of temperature-controlled solutions to protect products throughout transit, and passive solutions,
- Real-time tracking of cold chain shipments has become increasingly important, enabling teams to proactively monitor shipments and identify potential risks.
The European Commission in December issued the first approval of an allogeneic T-cell therapy in the world, a significant milestone for the cell and gene therapy sector. The landmark approval reflects the potential promise of pharmaceutical products currently in development and also highlights a broader industry trend: a growing percentage of products – from vaccines to cell and gene therapies – require cold chain storage and handling.